Tuberous Sclerosis Global Clinical Trials Review, H2, 2016
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
usiness opportunities<br />
Supports understanding of trials count and enrollment trends by country in global<br />
therapeutics market<br />
Aids in interpreting the success rates of clinical trials by providing a comparative scenario<br />
of completed and uncompleted (terminated, suspended or withdrawn) trials<br />
Facilitates clinical trial assessment of the indication on a global, regional and country level<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 3<br />
List of Figures 4<br />
Report Guidance 5<br />
<strong>Clinical</strong> <strong>Trials</strong> by Region 6<br />
<strong>Clinical</strong> <strong>Trials</strong> and Average Enrollment by Country 7<br />
Top Five Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in AsiaPacific 9<br />
Top Five Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in Europe 10<br />
Top Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in North America 11<br />
Top Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in Central and South America 12<br />
<strong>Clinical</strong> <strong>Trials</strong> by G7 Countries: Proportion of <strong>Tuberous</strong> <strong>Sclerosis</strong> to Genetic Disorders<br />
<strong>Clinical</strong> <strong>Trials</strong> 13<br />
<strong>Clinical</strong> <strong>Trials</strong> by Phase in G7 Countries 14<br />
<strong>Clinical</strong> <strong>Trials</strong> in G7 Countries by Trial Status 15<br />
<strong>Clinical</strong> <strong>Trials</strong> by E7 Countries: Proportion of <strong>Tuberous</strong> <strong>Sclerosis</strong> to Genetic Disorders<br />
<strong>Clinical</strong> <strong>Trials</strong> 16<br />
<strong>Clinical</strong> <strong>Trials</strong> by Phase in E7 Countries 17<br />
<strong>Clinical</strong> <strong>Trials</strong> in E7 Countries by Trial Status 18<br />
<strong>Clinical</strong> <strong>Trials</strong> by Phase 19<br />
In Progress <strong>Trials</strong> by Phase 20<br />
<strong>Clinical</strong> <strong>Trials</strong> by Trial Status 21<br />
<strong>Clinical</strong> <strong>Trials</strong> by End Point Status 22<br />
Subjects Recruited Over a Period of Time 23<br />
<strong>Clinical</strong> <strong>Trials</strong> by Sponsor Type 24<br />
Prominent Sponsors 25<br />
Top Companies Participating in <strong>Tuberous</strong> <strong>Sclerosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> 26<br />
Prominent Drugs 27<br />
Latest <strong>Clinical</strong> <strong>Trials</strong> News on <strong>Tuberous</strong> <strong>Sclerosis</strong> 28<br />
Sep 06, <strong>2016</strong>: Drug reduces seizure frequency in children with tuberous sclerosis complex<br />
28<br />
<strong>Clinical</strong> Trial Profile Snapshots 29<br />
Appendix 71<br />
Abbreviations 71<br />
Definitions 71<br />
Research Methodology 72<br />
Secondary Research 72<br />
About <strong>Global</strong>Data 73<br />
Contact Us 73<br />
Disclaimer 73<br />
Source 74
Change language